Switch to
More onapp

How to use scorecard? Learn more

Suven Life Sciences Ltd

SUVEN
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,314 cr, stock is ranked 977
High RiskStock is 4.79x as volatile as Nifty
106.150.50 (+0.47%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Low

Profitability and efficiency haven't been upto the mark

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,314 cr, stock is ranked 977
High RiskStock is 4.79x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
-21.81
PB RatioPB Ratio
6.17
Dividend YieldDiv. Yield
Sector PESector PE
52.36
Sector PBSector PB
5.99
Sector Div YldSctr Div Yld
0.56%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.

Financial TrendFinancial statements 

202020212022202328.4521.2317.1627.99-94.22-72.16-121.99-118.27
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnFeb 6, 2024

Suven Life Sciences Limited has informed the Exchange regarding a press release dated February 06, 2024, titled "Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder study in USA". | Download

Suven Life Sciences Limited has informed the Exchange regarding a press release dated February 06, 2024, titled "Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder study in USA". | Download

Notice Of Shareholders Meetings-XBRL 
Announced OnFeb 2, 2024

SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot | Download

SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot | Download

Cash Dividend 
Ex. DateFeb 17, 2021

Interim • Div/Share: ₹ 1

See all events